Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial
- 16 November 2020
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 24 (2) , 492-502
Abstract
Background Specific treatment strategies are sorely needed for scirrhous-type gastric cancer still, which has poor prognosis. Based on the promising results of our previous phase II study (JCOG0210), we initiated a phase III study to confirm the efficacy of neoadjuvant chemotherapy (NAC) in type 4 or large type 3 gastric cancer. Methods Patients aged 20–75 years without a macroscopic unresectable factor as confirmed via staging laparoscopy were randomly assigned to surgery followed by adjuvant chemotherapy with S-1 (Arm A) or NAC (S-1plus cisplatin) followed by D2 gastrectomy plus adjuvant chemotherapy with S-1 (Arm B). The primary endpoint was overall survival (OS). Results Between October 2005 and July 2013, 316 patients were enrolled, allocating 158 patients to each arm. In Arm B, in which NAC was completed in 88% of patients. Significant downstaging based on tumor depth, lymph node metastasis, and peritoneal cytology was observed using NAC. Excluding the initial 16 patients randomized before the first revision of the protocol, 149 and 151 patients in arms A and B, respectively, were included in the primary analysis. The 3-year OS rates were 62.4% [95% confidence interval (CI) 54.1–69.6] in Arm A and 60.9% (95% CI 52.7–68.2) in Arm B. The hazard ratio of Arm B against Arm A was 0.916 (95% CI 0.679–1.236). Conclusions For type 4 or large type 3 gastric cancer, NAC with S-1 plus cisplatin failed to demonstrate a survival benefit. D2 surgery followed by adjuvant chemotherapy remains the standard treatment.Keywords
Funding Information
- National Cancer Center (23-A-19, 26-A-4, 29-A-3, 2020-J-3)
- Ministry of Health, Labour and Welfare of Japan (H19-15, H22-23, H22-27)
This publication has 23 references indexed in Scilit:
- Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A)Gastric Cancer, 2014
- Is Preoperative Chemotherapy Followed by Surgery the Appropriate Treatment for Signet Ring Cell Containing Adenocarcinomas of the Esophagogastric Junction and Stomach?Annals of Surgical Oncology, 2014
- Phase II study of preoperative chemotherapy with S‐1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210)Journal of Surgical Oncology, 2013
- Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric CancerJournal of Clinical Oncology, 2011
- Gastric linitis plastica: which role for surgical resection?Gastric Cancer, 2011
- Signet Ring Cell Histology is an Independent Predictor of Poor Prognosis in Gastric Adenocarcinoma Regardless of Tumoral Clinical PresentationAnnals of Surgery, 2009
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006
- Japanese Classification of Gastric Carcinoma - 2nd English Edition - Response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteriaGastric Cancer, 2001
- Japanese Classification of Gastric Carcinoma – 2nd English Edition –Gastric Cancer, 1998
- Discrete Sequential Boundaries for Clinical TrialsBiometrika, 1983